Trade names Aggrastat
Pregnancy category AU: B1
Routes of administration-intravenous
Protein binding 65%
Elimination half-life 2 hours
It is an antiplatelet medication.
It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors.
It works by blocking the activation of a protein called glycoprotein IIb/IIIa, which is responsible for the formation of blood clots.
It is a synthetic, non-peptide inhibitor of the interaction of fibrinogen with the integrin glycoprotein IIb/IIIa on human platelets.
Tirofiban is administered intravenously in a hospital setting, and it is usually given to people who are undergoing certain medical procedures, such as angioplasty or stent placement.
Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa.
Tirofiban is indicated to reduce the rate of thrombotic cardiovascular events: combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure in people with non-ST elevation acute coronary syndrome.
It is a fast acting, highly selective, low molecular weight, non-peptide, glycoprotein IIB/IIIa receptor inhibitor with the short half-life that allows bleeding time to revert to normal within approximately three hours after its administration is stopped.
It has a rapid onset and short duration of action after proper IV administration.
Coagulation parameters turn to normal 4 to 8 hours after the drug is withdrawn.
Tirofiban is contraindicated in patients with:
Known hypersensitivity to any component of tirofiban.
History of thrombocytopenia with prior exposure to tirofiban.
Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.
In a group of patients with stroke of recent onset, or progression of stroke symptoms, and non-occluded large and medium size cerebral vessels intravenous Tirofiban was associated with a greater likelihood of improved outcome than low-dose aspirin. (ZI.W).
Bleeding is the most commonly reported adverse reaction.
Major bleeding has occurred in 1.4% of patients and minor bleeding in 10.5%.
There are no adequate and well controlled studies in pregnant women.
It is not known whether tirofiban is excreted in human milk.
The concomitant application of warfarin or other oral anticoagulants may increase the risk of serious bleeding events.
Tirofiban is a modified version of a molecule found in the venom of the saw-scaled viper Echis carinatus.